Innoviva, Inc.
INVANASDAQHealthcare● Active
$22.33
$-0.19(-0.84%)
Market Cap$1.6B
P/E Ratio—
52W High$25.15
52W Low$16.52
Innoviva, Inc. (INVA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INVA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.44
Est. $0.43 · +2.3%
Revenue
$0.10B
Est. $0.10B · -3.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 4-Quarter EPS Beat Streak
INVA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.44 | — | — | — | $0.11B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $0.43 | $0.44 | +2.3% | $0.10B | $0.10B | -3.5% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.34 | $1.94 | +470.6% | $0.11B | $0.10B | +11.7% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.46 | $1.08 | +134.8% | $0.11B | $0.10B | +6.2% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.57 | $0.77 | +35.1% | $0.10B | $0.09B | +10.3% |
| ▼ Q2 FY2025 | May 7, 2025 | $0.29 | $0.25 | -13.8% | $0.09B | $0.08B | +7.2% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $0.34 | $0.57 | +67.7% | $0.09B | $0.09B | -0.8% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $0.27 | $0.02 | -92.6% | $0.09B | $0.09B | +1.5% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$0.44
EPS Est.
$0.43
EPS Surpr.
+2.3%
Revenue
$0.10B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$1.94
EPS Est.
$0.34
EPS Surpr.
+470.6%
Revenue
$0.11B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$1.08
EPS Est.
$0.46
EPS Surpr.
+134.8%
Revenue
$0.11B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.77
EPS Est.
$0.57
EPS Surpr.
+35.1%
Revenue
$0.10B
Q2 FY2025
May 7, 2025Miss
EPS Actual
$0.25
EPS Est.
$0.29
EPS Surpr.
-13.8%
Revenue
$0.09B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$0.57
EPS Est.
$0.34
EPS Surpr.
+67.7%
Revenue
$0.09B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$0.02
EPS Est.
$0.27
EPS Surpr.
-92.6%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.62 | $0.65 | $0.67 | 1 |
| Q3 FY2027 | $0.59 | $0.60 | $0.63 | 1 |
| Q2 FY2027 | $0.60 | $0.62 | $0.64 | 1 |
| Q1 FY2027 | $0.52 | $0.54 | $0.56 | 1 |
| Q4 FY2026 | $0.53 | $0.55 | $0.57 | 1 |
| Q3 FY2026 | $0.50 | $0.51 | $0.53 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +2.3% | $22.65 | $22.52 | -0.57% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +470.6% | $23.42 | $24.24 | +3.50% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +134.8% | $18.15 | $18.23 | +0.44% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +35.1% | $18.44 | $18.25 | -1.03% |
| ▼ Q2 FY2025 | May 7, 2025 | -13.8% | $18.71 | $18.74 | +0.16% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +67.7% | $18.03 | $17.90 | -0.72% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -92.6% | $19.43 | $19.92 | +2.52% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +183.3% | $18.99 | $18.84 | -0.79% |
Q2 FY2026-0.57%
Report Date
May 6, 2026
EPS Beat/Miss
+2.3%
Price Before
$22.65
Price After
$22.52
Q1 FY2026+3.50%
Report Date
Feb 25, 2026
EPS Beat/Miss
+470.6%
Price Before
$23.42
Price After
$24.24
Q4 FY2025+0.44%
Report Date
Nov 5, 2025
EPS Beat/Miss
+134.8%
Price Before
$18.15
Price After
$18.23
Q3 FY2025-1.03%
Report Date
Aug 6, 2025
EPS Beat/Miss
+35.1%
Price Before
$18.44
Price After
$18.25
Q2 FY2025+0.16%
Report Date
May 7, 2025
EPS Beat/Miss
-13.8%
Price Before
$18.71
Price After
$18.74
Q1 FY2025-0.72%
Report Date
Feb 26, 2025
EPS Beat/Miss
+67.7%
Price Before
$18.03
Price After
$17.90
Q4 FY2024+2.52%
Report Date
Nov 6, 2024
EPS Beat/Miss
-92.6%
Price Before
$19.43
Price After
$19.92
Q3 FY2024-0.79%
Report Date
Jul 31, 2024
EPS Beat/Miss
+183.3%
Price Before
$18.99
Price After
$18.84
Avg Beat Reaction+0.14%
Avg Miss Reaction+1.34%
Beat Rate6 / 8 quarters
Largest Move+3.50% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INVA ends December
Innoviva, Inc. (INVA) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.44 — beating the analyst consensus of $0.43 by +2.3%. INVA has beaten EPS estimates for 4 consecutive quarters. The next INVA earnings date is expected around September 1, 2026.
Each quarter, investors track INVA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INVA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INVA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INVA earnings · 5 questionsInnoviva, Inc.'s next earnings report is expected around September 1, 2026. INVA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INVA historically reports after market close (AMC).
INVA earnings datewhen is INVA earningsINVA next earnings datewhen does INVA report earningsINVA earnings calendar
▸ Source: FMP · Innoviva, Inc. SEC filings · US GAAP · Innoviva, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026